Related Experiment Videos

Hepatocyte growth factor expression in human cancer and therapy with specific inhibitors

R Haddad1, K E Lipson, C P Webb

  • 1Laboratory of Tumor Metastasis and Angiogenesis, Van Andel Research Institute, Grand Rapids, MI 49503, USA.

Anticancer Research
|March 23, 2002
PubMed

Insights

Hepatocyte growth factor/Scatter Factor (HGF/SF) and Met receptor signaling drive cancer progression. Targeting this pathway offers a promising therapeutic strategy for various human tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Hepatocyte growth factor/Scatter Factor (HGF/SF) activates the Met receptor tyrosine kinase.
  • This activation leads to diverse cellular responses like proliferation, motility, and invasion.
  • Aberrant HGF/SF-Met signaling is implicated in tumorigenesis, angiogenesis, and metastasis.

Purpose of the Study:

  • To review the critical role of HGF/SF-Met signaling in cancer development.
  • To discuss the therapeutic potential of targeting the HGF/SF-Met pathway in human cancers.

Main Methods:

  • Literature review of existing studies on HGF/SF-Met signaling in cancer.
  • Analysis of evidence linking HGF/SF-Met expression to tumor progression and metastasis.

Main Results:

  • Compelling evidence supports a key role for HGF/SF-Met signaling in tumorigenesis.
  • Frequent aberrant HGF/SF-Met expression correlates with progressive disease in various human tumors.

Conclusions:

  • The HGF/SF-Met pathway is a significant driver of cancer.
  • Targeting HGF/SF-Met represents a viable therapeutic strategy for cancer intervention.

Related Concept Videos